Abstract
Imatinib related non-haematological side-effects are reported in <10% of chronic myeloid leukaemia patients and include oedema, weight gain, nausea, vomiting and muscle cramps. Cutaneous reactions are well-recognized events occurring mostly in patients treated at doses of 600 mg/d and higher, either in stable or progressive disease. We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma.
(c) Blackwell Munksgaard 2005
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Benzamides
-
Carcinoma / chemically induced*
-
Carcinoma / pathology
-
Drug Eruptions* / pathology
-
Edema / chemically induced
-
Edema / pathology
-
Female
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Nausea / pathology
-
Piperazines / administration & dosage
-
Piperazines / adverse effects*
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects*
-
Skin Neoplasms / chemically induced*
-
Skin Neoplasms / pathology
-
Vomiting / chemically induced
-
Vomiting / pathology
-
Weight Gain
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate